Overview
ENSC market data
Price History
ENSC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.98 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -250.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.23 – $2.75 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.2M · P/B 2.18 · P/S 1.11.
Company News
Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M EstimateBenzinga · Aug 13, 2026, 8:45 PM
8-K filing — Ensysce Biosciences, Inc. (ENSC)SEC EDGAR · Aug 13, 2026, 8:20 PM
Nasdaq Down 50 Points; US Foods Posts Upbeat EarningsBenzinga · Aug 6, 2026, 1:43 PM
Ensyce Biosciences shares are trading higher after the company announced the acquisition of Cy Biopharma and up to $77 million in private financing.Benzinga · Aug 6, 2026, 1:27 PM
Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028Benzinga · Aug 6, 2026, 12:06 PM
Ensysce Biosciences shares are trading higher after the company received a U.S. patent notice titled "compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof."Benzinga · Aug 4, 2026, 12:15 PM
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 4, 2026, 8:42 AM
Ensysce Biosciences shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF"Benzinga · Aug 3, 2026, 8:41 PM
Ensysce Biosciences Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF".Benzinga · Aug 3, 2026, 7:59 PM
Ensysce Biosciences Issued $5.3M From National Institutes On Drug Abuse To Support Development Of Multi-Pill Abuse Resistance Overdose-Protection TechnologyBenzinga · Jul 14, 2026, 12:02 PM